EA200801798A1 - Виросомоподобные везикулы, содержащие антигены, производные от gp41 - Google Patents

Виросомоподобные везикулы, содержащие антигены, производные от gp41

Info

Publication number
EA200801798A1
EA200801798A1 EA200801798A EA200801798A EA200801798A1 EA 200801798 A1 EA200801798 A1 EA 200801798A1 EA 200801798 A EA200801798 A EA 200801798A EA 200801798 A EA200801798 A EA 200801798A EA 200801798 A1 EA200801798 A1 EA 200801798A1
Authority
EA
Eurasian Patent Office
Prior art keywords
virosomoprogable
vesiculas
antigens derived
containing antigens
vesicle
Prior art date
Application number
EA200801798A
Other languages
English (en)
Other versions
EA018084B1 (ru
Inventor
Сильвен Флёри
Морган Бомсель
Ринальдо Цурбригген
Original Assignee
Майметикс Корпорейшн
Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль (Инсэрм)
Певион Биотех Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Майметикс Корпорейшн, Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль (Инсэрм), Певион Биотех Лтд. filed Critical Майметикс Корпорейшн
Publication of EA200801798A1 publication Critical patent/EA200801798A1/ru
Publication of EA018084B1 publication Critical patent/EA018084B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к виросомоподобной везикуле, содержащей, по меньшей мере, антиген, производный oт gp41, или его аналог, где указанный антиген, производный от gp41, локализован на внешней поверхности и/или инкапсулирован внутри указанной везикулы и находится в подходящей конфигурации для того, чтобы придать указанной виросомоподобной везикуле способность вызывать иммунный ответ против белка gp41 вируса иммунодефицита человека (ВИЧ).
EA200801798A 2006-03-03 2007-03-02 Виросомоподобные везикулы, содержащие антигены, производные от gp41, и их применение EA018084B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2006/000466 WO2007099387A1 (en) 2006-03-03 2006-03-03 Virosome-like vesicles comprising gp41-derived antigens
PCT/IB2007/000502 WO2007099446A2 (en) 2006-03-03 2007-03-02 Virosome-like vesicles comprising gp41-derived antigens

Publications (2)

Publication Number Publication Date
EA200801798A1 true EA200801798A1 (ru) 2009-06-30
EA018084B1 EA018084B1 (ru) 2013-05-30

Family

ID=37027640

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801798A EA018084B1 (ru) 2006-03-03 2007-03-02 Виросомоподобные везикулы, содержащие антигены, производные от gp41, и их применение

Country Status (13)

Country Link
US (1) US9216156B2 (ru)
EP (1) EP1991564B1 (ru)
CN (1) CN101437841B (ru)
AP (1) AP2008004615A0 (ru)
BR (1) BRPI0708519B8 (ru)
CA (1) CA2644282C (ru)
DK (1) DK1991564T3 (ru)
EA (1) EA018084B1 (ru)
ES (1) ES2437585T3 (ru)
PL (1) PL1991564T3 (ru)
PT (1) PT1991564E (ru)
WO (2) WO2007099387A1 (ru)
ZA (1) ZA200807592B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111560352A (zh) * 2020-06-02 2020-08-21 新疆农业大学 一种病毒样囊泡及其制备方法和应用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2543072A1 (en) * 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
CN101052383B (zh) 2004-09-17 2013-01-30 马萨诸塞大学 用于溶酶体酶缺乏症的组合物和其用途
JP2011517279A (ja) 2007-10-29 2011-06-02 ユニバーシティ オブ マサチューセッツ 核酸（ｓｉＲＮＡ）送達用の酵母細胞壁粒子（ＹＣＷＰ）多層状ナノ粒子
US20110033499A1 (en) * 2008-04-21 2011-02-10 Marine Biotechnology Australia Pty Ltd Anti-viral nutraceutical
CA2750067C (en) * 2009-02-06 2018-08-21 Mymetics Corporation Splitting gp41
CA2750058C (en) 2009-02-06 2017-11-28 Mymetics Corporation Novel gp41 antigens
WO2011128720A1 (en) 2010-04-14 2011-10-20 Mymetics Corporation Trans-activator of transcription protein
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9518087B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20130196903A1 (en) * 2010-08-11 2013-08-01 Jv Bio Srl Multimeric Inhibitors of Viral Fusion and Uses Thereof
JP2014504184A (ja) 2010-12-01 2014-02-20 スパイナル・モデュレーション・インコーポレイテッド 神経構造への薬剤の直接送達
WO2015000831A1 (en) * 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
JP6744227B2 (ja) 2014-02-21 2020-08-19 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 糖標的化治療剤
JP6466571B2 (ja) 2014-09-12 2019-02-06 ベステウィル ホールディング ビー．ブイ．Ｂｅｓｔｅｗｉｌ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． アジュバント添加ビロソームを提供する方法およびそれによって得られるアジュバント添加ビロソーム
WO2017044940A1 (en) * 2015-09-10 2017-03-16 Washington State University Cell membrane-formed nanoscale vesicles and methods of using thereof
JP7395355B2 (ja) 2017-05-08 2023-12-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 膜融合を促進するための組成物およびその使用
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN107462534B (zh) * 2017-08-15 2019-11-29 吉林师范大学 一种检测生物巯基化合物的体系及其检测方法
CA3091478A1 (en) 2018-02-17 2019-08-22 Flagship Pioneering Innovations V, Inc. Compositions and methods for membrane protein delivery
KR20210021473A (ko) 2018-05-15 2021-02-26 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 푸소솜 조성물 및 그의 용도
MX2021000308A (es) 2018-07-09 2021-06-08 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
US20230068547A1 (en) 2018-11-14 2023-03-02 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
WO2020102485A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
JP2022507453A (ja) 2018-11-14 2022-01-18 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｔ細胞送達のためのフソソーム組成物
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
WO2020121062A1 (en) 2018-12-12 2020-06-18 Anergis S.A. Methods of improving efficacy of allergy vaccines
US20230190871A1 (en) 2020-05-20 2023-06-22 Sana Biotechnology, Inc. Methods and compositions for treatment of viral infections
JP2023540705A (ja) 2020-08-28 2023-09-26 サナ バイオテクノロジー，インコーポレイテッド 修飾された抗ウイルス結合剤
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
WO2023102550A2 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023150647A1 (en) 2022-02-02 2023-08-10 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229703T2 (de) 1991-05-08 2000-04-27 Schweiz Serum & Impfinst Wiederhergestellte Influenza-Virosomen mit immunostimulierenden und immunoverstärkenden Eigenschaften und diese enthaltende Impfstoffe
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
AU2003253873A1 (en) 2002-07-15 2004-02-02 Aviza Technology, Inc. Apparatus and method for backfilling a semiconductor wafer process chamber
EA008497B1 (ru) 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
RU2390525C2 (ru) 2003-07-30 2010-05-27 Майметикс Корпорейшн Новая растворимая и стабилизированная тримерная форма полипептидов gp41
CA2543072A1 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
WO2005111079A2 (en) * 2004-05-14 2005-11-24 The United States Of America As Represented By The Secretary Department Of Health And Human Services Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111560352A (zh) * 2020-06-02 2020-08-21 新疆农业大学 一种病毒样囊泡及其制备方法和应用
CN111560352B (zh) * 2020-06-02 2023-03-24 新疆农业大学 一种病毒样囊泡及其制备方法和应用

Also Published As

Publication number Publication date
BRPI0708519B1 (pt) 2019-04-16
CN101437841A (zh) 2009-05-20
ZA200807592B (en) 2009-12-30
CA2644282C (en) 2017-06-13
EP1991564A2 (en) 2008-11-19
EP1991564B1 (en) 2013-09-11
CN101437841B (zh) 2013-07-24
WO2007099446A3 (en) 2008-06-19
PL1991564T3 (pl) 2014-04-30
CA2644282A1 (en) 2007-09-07
US9216156B2 (en) 2015-12-22
ES2437585T3 (es) 2014-01-13
WO2007099387A1 (en) 2007-09-07
DK1991564T3 (da) 2013-12-16
US20090202622A1 (en) 2009-08-13
EA018084B1 (ru) 2013-05-30
AP2008004615A0 (en) 2008-10-31
PT1991564E (pt) 2013-11-25
BRPI0708519B8 (pt) 2021-05-25
BRPI0708519A8 (pt) 2019-01-08
BRPI0708519A2 (pt) 2011-05-31
WO2007099446A2 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
ATE397014T1 (de) Hiv-peptide, antigene und impfstoffzusammensetzungen
WO2003083058A3 (en) Replikin peptides in rapid replication of glioma cells and in influenza epidemics
WO2002020554A3 (en) Hiv peptides from conserved regions in gag p17 and 924 and their application in e.g. vaccines
DE68927348T2 (de) Künstlicher impfstoff gegen aids-virus
DE60121136D1 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
WO2004084805A3 (en) Acetylated tat polypeptides and methods of use thereof
EP1200109A4 (en) USE OF PEPTIDE NUCLEIC ACID COMPOUNDS TO TRIGGER CELLULAR IMMUNE RESPONSES TO HEPATITIS C
WO2004080403A3 (en) Influenza virus vaccine
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
WO2002074795A3 (en) Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
CY1106310T1 (el) Καθορισμος hbv αντιγονων για χρηση σε εμβολια
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
WO2006045532A3 (en) Virosome particles comprising antigens from influenza virus and hepatitis b virus
WO2002020555A3 (en) Hiv peptides from tat, rev and wef conserved regions and their application as e.g.vaccine components
WO2006024240A3 (es) Composición vacunal contra el virus de la hepatitis c.
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
WO2005021574A3 (de) Induktion antiviraler neutralisierender antikörper beim menschen und beim tier
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
RU2000106709A (ru) Пептиды-имитаторы консервативного эпитопа белка gp41 вируса иммунодефицита человека типа 1, узнаваемого вируснейтрализующими моноклональными антителами 2f5
HUP0303423A2 (hu) HIV elleni természetes ellenanyag
FR2839721B1 (fr) Antigene polypeptidique induisant des anticorps neutralisant le vih
DK1237571T3 (da) Toscana-virus-nukleinprotein
WO2005118622A3 (en) Naturally processed measles virus peptides eluted from class ii hla molecules

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ